Counsyl Reliant™ Cancer Screen

Help your patients
get ahead of hereditary cancers

The Counsyl Reliant Cancer Screen is designed with prevention in mind so you can easily incorporate hereditary cancer screening into your practice.

Why offer hereditary cancer screening

We believe that no person should find out they have a gene mutation that increases their risk for cancer, by being diagnosed with cancer.

90% of “high-risk” women
are not screened for BRCA1/2.1

Over 50% of hereditary cancers
are caused by genes other than BRCA1/2.2

Why Counsyl Reliant

Rigor in every result
with the Counsyl Reliant Cancer Screen

Clinical actionability

All genes on the Comprehensive Panel have medical management guidelines. To learn more about what the guidelines recommend for each gene on our panel, access our

Guide to the Reliant Cancer Screen >

Validated accuracy

Our CLIA-certified clinical genomics lab is among the most automated and advanced in the world, allowing for reduced costs and rapid turnaround times. Our next generation sequencing platform is scientifically validated, with >99.99% sensitivity, specificity, and accuracy.

Read our peer-reviewed validation study 3>

Extensive curation experience

Over 20,000 gene variants have been curated and classified to date by our multidisciplinary team of 25+ scientists.

Learn more about our curation expertise >


The supporting services through Counsyl Complete helps seamlessly integrate hereditary cancer screening into your practice workflow.


We make it easy to qualify, educate, and order screening for your patients. Third party pre-test counseling is available when required by insurance.


We provide prior authorization assistance and strive to make screening accessible for more patients.


We automate the management of results and follow up with patients.


Our board-certified genetic counselors are available on-demand for all Counsyl patients, with positive or negative results.


About the test

The Counsyl Reliant Cancer Screen utilizes next generation sequencing (NGS) to identify genetic mutations that are known to have an increased risk of cancer. By using the latest advancements in technology, we are able to provide a rapid turnaround time for results, averaging approximately 2 weeks. To learn more about what the guidelines recommend for each gene on our panel, access the Guide to the Counsyl Reliant Cancer Screen.

In addition to these panels, Counsyl has a variety of panels to choose from based on the needs of your individual practice.  

Associated cancers

Breast, ovarian, endometrial, colorectal, pancreatic, gastric, prostate, thyroid, melanoma, and neuroendocrine

Who to screen

Men and women with a personal or family history of cancer

Sample type

4mL blood, or saliva sample


Next generation sequencing (NGS) including deletion and duplication analysis

Turnaround time

Results in 2 weeks on average

Get started today

“I knew I wanted to find out whether I’d inherited the genetic mutation so I could do what I could to combat it.”

Victoria R.
Counsyl Reliant Cancer Screen patient,
negative for BRCA1 and BRCA2


  1. Bellcross CA, et al. Genet Med. 2015;17(1):43–50. Patel S et al. Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome. Am J Gastroenterol (2016)
  2. BRCA1/BRCA2 Frequency: Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014.
  3. Vysotskaia V, Hogan G, Gould G et al. Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment. Peer J. DOI 10.7717/peerj.3046
  4. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High Risk Assessment: Breast and Ovarian Cancer. Version 1.2018.
  5. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol.. 2002;20(6):1480-1490.
  6. Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer. 2004;3(3-4):259-264.